No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity

被引：2

作者：

Nomoto, Hidetoshi ^{[1
]}

Kutsuna, Satoshi ^{[1
]}

Okuma, Kazu ^{[3
]}

Kuramitsu, Madoka ^{[3
]}

Tezuka, Kenta ^{[3
]}

Ikebe, Emi ^{[3
]}

Saito, Sho ^{[1
,2
]}

Kinoshita, Noriko ^{[1
,2
,4
]}

Terada, Mari ^{[1
]}

Endo, Mio ^{[1
]}

Suzuki, Tetsuya ^{[1
,2
]}

Miyazato, Yusuke ^{[1
]}

Nakamoto, Takato ^{[1
]}

Inada, Makoto ^{[1
]}

Hamaguchi, Isao ^{[3
]}

Ohmagari, Norio ^{[1
,2
,4
]}

机构：

[1] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo, Japan

[2] Tohoku Univ, Emerging & Reemerging Infect Dis, Grad Sch Med, Sendai, Miyagi, Japan

[3] Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, Tokyo, Japan

[4] Natl Ctr Global Hlth & Med, Antimicrobial Resistance Clin Reference Ctr, Tokyo, Japan

来源：

JOURNAL OF INFECTION AND CHEMOTHERAPY | 2021年 / 27卷 / 04期

关键词：

Coronavirus; 2019; Severe acute respiratory syndrome; coronavirus; 2; RNA; Convalescent plasma; Passive immunization;

D O I：

10.1016/j.jiac.2021.01.004

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction: Convalescent plasma transfusion (CPT), a potential therapy for coronavirus disease 2019 (COVID-19), requires strict quality control of the donor blood. Whether to confirm the disappearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA (RNAemia) in convalescent donor blood or not is unclear. Reports recommending the proof of viral disappearance from the blood are controversial. Foreseeing CPT in treating COVID-19 patients in Japan, we investigated RNAemia in 100 convalescent donors with mild, moderate, and severe COVID-19. Methods: Between April 30 and July 30, 2020, we measured RNAemia in the plasma samples of donors with resolved COVID-19. Data on patients' demographics, comorbidities, pneumonia, treatment, and real-time polymerase chain reaction results for SARS-CoV-2 were collected. Date of onset of initial symptoms or date of positive testing (for asymptomatic patients) were self-reported by the patients. Disease severity was defined as: no, mild, moderate oxygen demand, or severe (requiring mechanical ventilation). Results: Of 100 donors (58 males [58.0%]; median age, 47 [range 22-69] years) screened as of July 30, 2020, 77 (77.0%); 19 (19.0%); and 4 (4.0%) had mild, moderate, and severe disease, respectively. Median time between onset and testing was 68.5 (range, 21-167) days. SARS-CoV-2 RNA was not detected in any of the plasma samples. Conclusion: RNAemia was not found in recovered COVID-19 patients at least 21, 27, and 57 days after the onset of mild, moderate, and severe symptoms. Our study may contribute to determining a suitable time for collecting convalescent plasma from COVID-19 patients and to future CPT use. (c) 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

引用

页码：653 / 655

页数：3